Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03545789 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

A Phase 1 study, sponsored by Invicro.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT03545789 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03545789, a Phase 1 study, has completed, sponsored by Invicro.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The overall goal of this protocol is to evaluate \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.

Interventions

  • DRUG [18F]MNI-958

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-03-12
Est. Completion 2020-02-06
Phase Phase 1

Sponsor

Invicro

14 total trials

What the Registry Record Tells You About NCT03545789

The ClinicalTrials.gov registry entry for NCT03545789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-958 is the first listed.

NCT03545789 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03545789 about?

NCT03545789 is a clinical study titled "Phase 1 Test-retest Evaluation of [18F]MNI-958 PET". The overall goal of this protocol is to evaluate \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.

What is the current status of trial NCT03545789?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-03-12. Estimated completion is 2020-02-06.

What interventions are being tested in trial NCT03545789?

The interventions under investigation include: [18F]MNI-958 (DRUG).

Who is sponsoring clinical trial NCT03545789?

This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.